WO2008085364A1 - Apparatus and method for treating and dispensing a material into tissue - Google Patents
Apparatus and method for treating and dispensing a material into tissue Download PDFInfo
- Publication number
- WO2008085364A1 WO2008085364A1 PCT/US2007/025989 US2007025989W WO2008085364A1 WO 2008085364 A1 WO2008085364 A1 WO 2008085364A1 US 2007025989 W US2007025989 W US 2007025989W WO 2008085364 A1 WO2008085364 A1 WO 2008085364A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment module
- chamber
- treated
- plunger
- oxygen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
- A61B17/3478—Endoscopic needles, e.g. for infusion
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B13/00—Oxygen; Ozone; Oxides or hydroxides in general
- C01B13/02—Preparation of oxygen
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B13/00—Oxygen; Ozone; Oxides or hydroxides in general
- C01B13/10—Preparation of ozone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
- A61B2017/00238—Type of minimally invasive operation
- A61B2017/00261—Discectomy
Definitions
- the present invention relates generally to an apparatus for administering a therapeutic agent into tissue and in particular, for the creation and administration of a fluidic therapeutic agent into a tissue using a portable device.
- Back joint disc or tendon pain is a common and potentially debilitating ailment that affects an estimated 80% of the worldwide population at least once in a lifetime.
- the cause of the pain can be attributed to a degenerated intervertebral disc that has further deteriorated into a condition known as disc herniation. This occurs when the disc nucleus pulposus extrudes through a tear or fissure in the outer lining of the disk, thereby exerting pressure on spinal nerves.
- the compression caused by the herniated nucleus leads to inflammation and is directly responsible for the pain felt down the leg (also referred to as sciatica).
- Available treatments for this type of back pain vary according to the severity of the hernia.
- Dr. Cesare Verga proposed the use of ozone/oxygen mixtures to treat the pathology of a herniated disk.
- Inflammation can occur at a site where a tendon or a ligament insert to bone or pass through a sheath from trauma, tension, over use or disease.
- Inflammation can develop through pathologies of any joint, and these may again include the inflammatory arthropatic conditions of rheumatoid arthritis, psoriatic arthritis and the like, or osteoarthritis.
- Joints that may be involved in these processes that are amenable to the administration of a therapeutic agent such as oxygen-ozone mixtures or excited, energetic, pure oxygen include the synovial joints such as the, temporomandibular joint, the hip joint, knee joint, ankle joint, elbow joint or sacro-iliac joint.
- Vertebral facet and sacro-iliac joints may also benefit, inflammatory involvement of joints in the hand, wrist and feet with rheumatoid arthritis, osteoarthritis or a repetitive injury through sports or occupational such as carpal tunnel syndrome.
- the inflammatory and arthritic or degenerative discussions described above are usually treated with a combination of anti-inflammatory agents such as ibuprofen, or more powerful drugs such as steroids or chemotherapy such as methotrexate. It is a common medical practice to inject steroid medications or lidocaine directly into the inflamed tissue or joint. This is often done repeatedly. These drugs can be associated with side effects of infection and even death from gastric ulcer bleeding or immunosurpression and infection.
- ozone therapy whether with oxygen- ozone mixtures or excited, energetic, pure oxygen as a gas or dissolved in a liquid has advantages over the current practice.
- Lavage of a surgical space prior to placement of a permanent surgical implant such as a hip or knee prosthesis, or pacemaker or treatment of an infected joint can be facilitated by the use of oxygen-ozone mixtures or excited, energetic, pure oxygen as a sterilizing substance.
- a colostomy stoma can be created such that the adhesive disk is infused with oxygen-ozone mixtures or excited, energetic, pure oxygen as a gas or dissolved in a liquid to aid in healing and inhibit infection.
- the post surgical recovery from sternotomy after cardiac surgery is often complicated by wound infection.
- Dental injection of oxygen-ozone mixtures or excited, energetic, pure oxygen as a gas or dissolved in a liquid may augment the preparation and repair of dental cavities, and aid in reduction of root canal inflammation or periodontal disease.
- kits for intervention in inflammatory and degenerative disease that are portable, disposable, or reusable, but aid in creating sterile, stable, ozone rapidly on demand.
- Figure 1 is a partially cutaway perspective view of an apparatus for administering a therapeutic agent in accordance with an embodiment of the invention
- Figure 2 is an exploded perspective view of the apparatus shown in Figure
- Figure 3 is side cross-sectional view of the material treatment module of Figure 1;
- Figure 4 is side cross-sectional view of another embodiment of the material treatment module of Figure 1;
- Figure 6a is a cutaway plan view of an alternative embodiment of the invention.
- Figure 6b is cross-sectional plan view of Figure 6a taken along line A-A;
- Figure 6c is detailed plan view of section B of Figure 6a;
- Figure 7a is a cutaway plan view of an alternative embodiment of the invention.
- Figure 7b is cross-sectional plan view of Figure 7a taken along line A-A; and [0025] Figure 7c is detailed plan view of section B of Figure 7a. DETAILED DESCRIPTION OF THE INVENTION
- the apparatus 10 includes a housing 12 that defines a chamber 14.
- the apparatus 10 or housing 12 includes a plunger 16 and a barrel 18 that define the chamber.
- the plunger has a first end 20 and a second end 22.
- the barrel 18 has a first end 24 that is open for receiving the first end 20 of the plunger 16 such that the barrel 18 movably engages the plunger 16.
- the barrel 18 also includes a second end 26.
- the first end 20 of the plunger 16 and the second end 26 of the barrel 18 form the chamber 14.
- the housing 12 may have a volume of less than about 150 cubic centimeters.
- the chamber 14 can hold a volume of material up to about 150 cubic centimeters. In another embodiment, the chamber 14 can hold a volume of no less than about 0.1 cubic centimeters. It will be appreciated that the range of volumes may coincide with the position of the plunger 16 within the barrel 18. For example, the plunger 16 may move within the barrel 18 between a fill position, where the first end 20 of the plunger 16 is within the first end 24 of the barrel 18, but not completely within the barrel 18, and a dispensing position, where the first end 20 of the plunger 16 is substantially within the barrel 18 such that the first end 20 of the plunger 16 is adjacent the second end 26 of the barrel 18.
- the chamber 14 is configured to retain a material.
- "Material” as used throughout this specification, means gas, liquid, gels, solids, or combinations thereof. Material may also be solids suspended or dispersed throughout liquids, gases, or gels.
- a precursor or starting material may be charged into the device to be treated by operation of the device to create a beneficial or therapeutic agent. Accordingly, the device 10 can be used to create treated material that acts as a beneficial agent.
- “precursor,” “precursor material,” and “starting material” are used synonymously. Additionally, “treated material,” “beneficial agent,” and “therapeutic agent” may be used synonymously.
- the device is used to make a precursor material into a beneficial agent and then deliver the beneficial agent to a desired place, usually within a body.
- the first end 20 of the plunger may be configured with a seal 28 to facilitate retention of the material within the chamber 14.
- the seal may be a gasket or flexible flange or other mechanical means known in the art. It will be appreciated by those of skill in the art that there are a variety of ways to retain material within the chamber 14, each of which are within the scope of this invention.
- An outer surface 30 of the barrel 18 may include graduations 32 to measure the amount of material in the chamber 14.
- the device 10 may be configured in such a way to facilitate moving the plunger 16 between the fill position and the dispensing position.
- the barrel 18 may include a handle finger holds 34 and the plunger 16 may be configured with a handle 36.
- the apparatus 10 includes a material treatment module
- the material treatment module 40 can take a variety of configurations.
- the material treatment module 40 may be positioned within the housing 12 or the barrel 18. In one embodiment, the material treatment module 40 is positioned within the plunger 16. In other embodiments, the material treatment module 40 may be positioned within the barrel 18. In still other embodiments, the material treatment module 40 may be positioned outside the housing 12. [ 0035 ]
- the material treatment module 40 is in operable communication with the chamber 14 such that precursor material in the chamber may come into contact with, and be treated by, the material treatment module 40.
- the treating or treatment of material means to alter the composition or properties of all or a portion of the material.
- treated material means material that has had its chemical composition or other properties altered or modified.
- the material treatment module 40 may an ozone generator for creating ozone and the resulting or treated material may be a mixture of oxygen and ozone.
- the material treatment module 40 may oxidize water to produce a treated material the consists of oxygen and ozone.
- the precursor material is an aqueous salt solution
- the material treatment module 40 may oxidize the ions in the solution to create a beneficial or therapeutic agent dissolved in the solution or emitted as a gas.
- chloride ions in a precursor material may, after interaction with the material treatment module 40, become chlorine gas under the reaction 2Cr ⁇ Cl 2 (1)
- bromide ions may become bromine under the reaction
- the material treatment module may be able to reduce the precursor material to form the beneficial or therapeutic treated material.
- the original or precursor material may be treated by the material treatment module 40 to alter a variety of characteristics of the precursor material, including without limitation, the concentration of a particular element such as oxygen, the pH of the material, the temperature of the material, the viscosity of the material, and the like.
- the material treatment module 40 is able to take a benign material that is easy to store, and create a reactive material that has therapeutic value.
- treating the material may be accomplished by a variety of methods, including without limitation, reducing the material, oxidizing the material, electrochemically altering the material, chemically altering the material, thermally altering the material, or using light to alter the material.
- material treatment module the treated material may be a beneficial agent with various properties, characteristics, or attributes that may be therapeutic to a user.
- the apparatus 10 allows for transportable, single or multiple point-of-use application of the beneficial agent.
- the apparatus 10 may also have means for controlling the liquid treating module 40.
- the device 20 may have an on/off switch 42 or other regulators.
- the apparatus 10 may include visible and/or audible displays or indicators 44 to help the user determine a status of the liquid treating module.
- the apparatus 10 may indicating when apparatus is treating material or when it has stopped treating material. It may also indicate whether treated material is in the chamber 14.
- the housing 12 may have an outlet 46 in material communication with the chamber 14 for releasing the treated material from the housing 12.
- the outlet 46 is a port configured in the second end 26 of the barrel 18.
- the outlet 46 may be configured to receive a needle 48.
- the outlet 46 may allow a needle 48 to be press fit into the outlet 46.
- the outlet 46 may also be threaded to receive a threaded end to the needle 48.
- the needle 48 may be attached to the outlet 46 by a Luer or other mechanical connection or fitting. It will be appreciated by those of skill in the art that the outlet 46 and needle 48 may be configured in a variety of ways in order to communicate with each other.
- the needle is in material communication with the outlet and thus, the chamber allows treated material to enter into the body and a specific site that will provide the most therapeutic value to the user.
- the apparatus 10 may also include a valve 50 to help control the movement of material between the chamber 14 and the needle 48.
- the valve is a stopcock valve.
- the valve may be positioned in closed state while material is being treated to prevent leakage of the material. Once a predetermined amount of material is treated, the valve may be positioned in an open state to allow the treated material to exit the apparatus 10.
- a controller 52 for controlling the amount of material treated by the material treatment module 40.
- the controller 52 in one embodiment may include a timing circuit 54 for controlling the length of time the material treatment module 40 is permitted to treat material.
- the controller 52 may include an ozone circuit 56 for controlling the generation of ozone.
- the controller 52 is in electrical communication with the material treatment module 40.
- the controller 52 is positioned within the plunger housing 53 and is used for controlling the amount of ozone generated by the material treatment module 40 which may be an ozone generator. It will be appreciated by those of skill in the art that the controller 52 may also include a relay circuit (not shown) in order for the controller 52 to properly control the function of the material treatment module 40.
- a power source 80 is in electrical communication with the material treatment module 40 and the controller 52.
- the power source 80 can be direct current or alternating current.
- the power source 80 includes a battery or a series of batteries positioned coaxially within the plunger 16.
- the controller 52 may include electronics capable of generating and delivering a high-voltage, high-frequency electrical signal to the material treatment module 40.
- the frequency of the signal can be between about one tenth of a kilohertz ("kHz") and about one thousand kHz. In one embodiment, the frequency is between about twenty kHz and about sixty kHz.
- the voltage of the electrical signal is between about one kilovolt and about twenty kilovolts. In one embodiment, the electrical signal is between about three kilovolts and about six kilovolts.
- the power supply 80 can also supply an electric current with a voltage between about one volt and about thirty volts.
- a switch 42 may be used to control the delivery of power by the power source 80.
- the switch and other electrical components communicate with each other electronically through wires or cables 60.
- the switch 42 may any number of electrical switches known in the art.
- the switch may be a toggle that allows a user to complete or break the circuit multiple times.
- the switch is a pull tab configured such that when the pull tab is pulled out of the apparatus 10, the circuit is complete and current is delivered to the material treatment module 40.
- the timing circuit 54 may automatically stop the generation or delivery of current at a predetermined time.
- the controller 52 or individual components 54 and 56 of the controller 52 may also include a buzzer or light source to provide an audible or visual signal or display to indicate whether the apparatus 10 is on or off, or status of the material treatment module 40.
- the apparatus 10 may include a display. It will be appreciated by those of skill in the art that the electronic components of the apparatus 40 may be hardwired to a circuit board 62 as shown, or may be controlled by a programmable microprocessor (not shown).
- the plunger 16 may include a plunger housing 62 having a first part 64 and a second part 66.
- the housing 62 parts 64 and 66 together form a hollow interior in which the controller 52 and power source 80 are housed.
- An end cap 65 may be configured at the first end 20 of the plunger 16 to help hold the interior components in place.
- the end cap 65 may be configured with a seal 28 to provide sealing engagement with the interior of the barrel 18.
- the end cap 65 may also be configured to help control the telescoping engagement of the plunger 16 within the barrel 18.
- the plunger housing parts 64 and 66 may be secured together by fastening hardware 68 known in the art such as nuts, bolts, washers, set screws, and the like.
- the housing halves of the plunger 16 and other parts of the apparatus 10 such as the barrel 18 may be made of molded plastic and attached together in their operational state. The attachment may be accomplished in a number of ways including without limitation, adhesion or other types of bonding, welding, crimping, ultrasonic coupling, thermal coupling, and the like.
- the housings halves may also be configured to matingly engage each other by press fitting, snap fitting, and the like. Fasteners 68 of all types known in the art may also be used. It will be appreciated by those of skill in the art that the individual components may be made and combined in a variety of ways to practice the teachings of the invention.
- the electronics and control components may be located in the barrel 18. In another embodiment, the electronics and control components may be located in a separate housing or module from the plunger 16 or barrel 18.
- the plunger 16 and barrel 18 may be made from any suitable material that is substantially rigid, such as glass, stainless steel, polycarbonate, high density polyethylene, chlorinated polyvinylchloride, silicone, ethylene-propylene terpolymer, and fluoropolymer materials, such as polytetrafluoroethylene, fluorinated ethylene-propylene, and the like. It will be appreciated by those of skill in the art that the material used to make the apparatus 10 should be capable of functioning properly in light of the particular type of material treatment being accomplished by the material treatment module 40.
- the plunger 16, barrel 18, and other components in contact with the material should be made of an inert material such as those listed above when exposed to ozone.
- the material should be able to withstand the range of heat being used.
- the housing must be compatible to ultraviolet light.
- the material treatment module 40 may be positioned within the end 20 of the plunger 16.
- the material treatment module 40 is an electrochemical cell 40 having a cathode 70, anode 72, and an electrolyte (see Figure 3).
- the chip 40 may be positioned within a cavity 69 configured within plunger 16.
- the material treatment module 40 is coaxial with the plunger and is open to and in communication with the chamber 14 defined by the first end 20 of the plunger 16 and the second end 26 of the barrel 18. Furthermore, it is to be understood that the material treatment module 40 may be disposed at any suitable position relative to the housing 12 of the apparatus 10. When the housing 12 is in the form of plunger 16/barrel 18 combination, the material treatment module 40 may be disposed at any suitable location between the first end 20 and the second end 22 of the plunger 16, or at any location between the first end 24 and the second end 26 of the interior of the barrel 18. In addition, the material treatment module 40 may also be disposed at any suitable location on an exterior surface of the device 10, or at a location outside the device where the material treatment module 40 is unattached to, but connected to, the device.
- the material treatment device 40 may also be a corona discharge device.
- the material treatment module 40 may also be an ultraviolet ("UV") light source.
- UV ultraviolet
- the power source 80, and electronic circuits 54, 56, circuit boards 62, cables 60 and controller 52 would be modified to allow for the proper function of the corona discharge device or UV light source.
- the UV light source device, electronics would need to provide a wavelength of the light between about 100 nm and about 700 nm or between about 140 nm and about 200 nm.
- the material treatment module 40 may be an open vessel for storing an ozonated gel and a heating element, such that activation of the heating element elevates a temperature of the gel causing desorption of ozone-oxygen mixture from the gel.
- the gel can be formed by sparging ozone through olive oil and then chilling the olive oil. The olive oil is chilled to a temperature of between about minus fifteen 0 C and about ten 0 C. It will be appreciated by those of skill in the art that a variety of material treatment module 40 options may be used alone or in combination to practice the teachings of this invention.
- a needle 48 attached to the outlet 46 may be of any desired material, length or gauge that may be desired according to the treated material being delivered.
- the treated material is an oxygen-ozone mixture of therapeutic value, the details of which will be discussed in greater detail below.
- the needle 48 can be a Chiba needle or Franceen needle or other suitable needle as will occur to those of skill in the art.
- FIG 3 a more detailed view of a material treatment module 40 according to the present invention is shown.
- the material treatment module 40 may be an electrochemical cell comprising a cathode 70, an anode 72, and an electrolyte 74.
- the electrolyte 74 is positioned between the cathode 70 and the anode 72.
- the power source (not shown) provides voltage across the cathode 70 and the anode 72 by means of wires 76.
- the material treatment module 40 can be an electrochemical ozone generator.
- An oxygen or air precursor material may interact with the material treatment module 40 such that an oxygen-ozone mixture is created. This mixture may be released from the electrochemical cell configuration of the material treatment module 40 by the electrolysis of water and the production of ozone and oxygen at the anode 72.
- an electric current is used with an applied voltage between about three volts and about twenty volts. In another embodiment, a voltage between about two volts and about ten volts is used.
- the material treating module 40 may be a surface-discharge corona.
- a dielectric material 174 may be positioned between a pair of electrodes 170 and 172.
- Wires 176 may be used to connect to a discharge electrode 170 and an induction electrode 172.
- the electrodes are incorporated within a high purity alumina or silica dielectric 174.
- the electrodes 170 and 172 contain without limitation, tungsten, platinum, nichrome, stainless steel or combination thereof.
- An alternative embodiment utilizes a more traditional gap- discharge, corona material treatment module 40 that utilizes a glass dielectric and low- frequency high voltage power.
- the device 10 is used to create treated gas in the form of oxidizing gas.
- the chamber 14 may contain a starting gas in the form of pure oxygen gas.
- An oxygen-ozone mixture is released from the corona discharge device 40 by passing the oxygen-containing gas through an electrical field originating from device 40 at a frequency between about one- tenth kilohertz ("kHz") and about one thousand kHz.
- a frequency between about twenty kHz and about sixty kHz is used.
- An electric current with a voltage between about one kilovolt and about twenty kilovolts and a more presently preferred voltage between about three kilovolts and about six kilovolts may also be used.
- the range of motion of the plunger 16 within the barrel 18, between the fill position and the dispensing position may be defined by a groove 17 configured within the plunger 16.
- a stop 19 configured within the barrel 18 may be positioned within the groove 17 to control the maximum fill volume of the barrel 18.
- multiple stops 19 can be incorporated to control both the fill and delivery volumes of the barrel 18. It will be appreciated by those of skill in the art that movement of the plunger 16 within the barrel 18 may be accomplished in a variety of ways known in the art. As stated above in connection with Figure 1 the first end 20 of the plunger 16 and the second 26 of the barrel 18 form a chamber 14 or an accumulator. The chamber 14 volume decreases as the plunger is moved from a fill position to a dispensing position.
- the device 10 may be in a position such that the chamber (seen best in Figure 1) is capable of holding a predetermined amount of material.
- This precursor material may be any volume of material to be treated by the device. In most embodiments, it is a precursor liquid, gas, gel, or combination thereof that will be treated by the device in order to generate a beneficial or therapeutic agent.
- Precursor material may by drawn into the chamber 14 by attaching the outlet 46 or an apparatus attached the outlet 46 such as a needle to the source of precursor material and drawing the plunger 16 toward the fill position. Precursor material may also be charged into the chamber 14 from an external source attached to the device 10 or distant from the device 10.
- Precursor material may be charged into the chamber 14 before packaging of the device or after the user has obtained the device 10. It will be appreciated by those of skill in the art that there are a number of ways to charge the device 10 or chamber 14 with precursor material.
- the precursor material may include, without limitation, air, oxygen, water, nitrogen, carbon dioxide, chlorine, bromine, and combinations thereof. It may also include a salt solution, either alone or in combination with the foregoing.
- the salt solution may include NaI, NaF, NaCl, NaBr, and the like.
- the precursor material may be in the form of a gas, liquid, gel, or combinations thereof.
- the precursor material may contain treated material.
- the device 10 may then be activated by engaging a switch 42 ( Figures 1 and 2), which allows activation of the power source 80 ( Figure 2), causing the material treatment module 40 to interact with the precursor material in the chamber 14. Depending upon the type of material treatment module 40 being used, activation of the device 10 creates or generates beneficial agent by treating the precursor material to create a treated material.
- the material treatment module 40 is an ozone generator in the form of a corona generator
- the precursor material is oxygen
- activating the device 10 causes the material treatment module 40 to emit a field that interacts with the oxygen in the chamber 14 thereby creating ozone mixed with oxygen, which is a beneficial agent.
- the plunger 16 is depressed to deliver ozone from the outlet 46.
- the stroke of plunger 16 is chosen so that, when fully depressed, material treatment module 40 may come into close proximity of the second end 26 of the barrel 18, but without actually coming into contact therewith.
- treated material may be material that has been altered or modified in any way by operation of the device 10.
- precursor material and treated material refer to material at different stages of single operation of the device 10.
- the precursor material is oxygen and the material treatment module 40 is an ozone generator
- activation of the device 10 will create a treated material consisting of a mixture of ozone and oxygen. If this mixture were stored and later charged into the device for a second application, this treated mixture would then be the precursor material for the second application of the device 10.
- the treated material is the therapeutic agent desired to be delivered to a patient.
- the treated material may include without limitation, ozone, oxygen, nitric oxide(s), chlorine, fluorine, chlorine dioxide, iodine, carbon dioxide, bromine, bromine dioxide, oxygen radicals; hydroxyl radicals; ionic oxygen; oxygen treated with energy and combinations thereof. At least a portion of the treated material may also include precursor material.
- the treated material may also include inert gases which can include, but are not limited to, nitrogen, helium, carbon dioxide, and/or combinations thereof.
- the barrel 318 has a first end 324 that is open for receiving the first end 320 of the plunger 316 such that the plunger 316 movably engages the barrel 318.
- the barrel 318 also includes a second end 326.
- the second end 326 of the barrel 318 may be configured with an outlet 346 that serves as the outlet 346 for the chamber 314.
- a needle 348 may include a first end 382 and a second end 384.
- the second end 384 of the needle 348 may be attached to the outlet 346 using a Luer or other mechanical connection or fitting.
- the material treatment module 40 is within the needle
- the needle 348 utilizes a flow-through electrochemical cell to create treated material in the form of a therapeutic agent.
- the electrochemical cell needle 348 includes an anode 370 and a cathode 372. Electric current is delivered to the anode 370 and cathode 372 by wires 376 attached to a power source 380.
- the chamber 314 is charged with precursor material or precursor or electrolyte 374.
- the electrochemical reaction between the material treatment module 340 and the precursor material can be controlled by the selection of electrode or electrolyte material.
- the electrodes 370 and 372 affect the electrochemical kinetics of the electroxidation/electroreduction reaction at the electrode 370 and 372.
- the power source is initiated to polarize the anode 370 and cathode 372 which generates therapeutic agent by electrooxidizing or electroreducing the precursor material as it is plunged out the chamber 314 and into the needle 348.
- the anode 370 is the metallic wall of the needle.
- the anode 370 and cathode 372 may be reversed for all embodiments.
- the timing and control of the applied voltage and/or current power source control the amount of beneficial agent that is produced by the material treatment module 40, and may be manual or automatic (i.e. programmable microprocessor controlled).
- the wires can be conductors that are printed on the inside of the chamber 314.
- the wires 376 are insulated and the electrodes 370 and 372 are conductive and selective for the desired beneficial agent.
- the electrodes 370 and 372 may be tungsten, platinum, stainless steel, nichrome, or aluminum configured in the needle 348.
- the material treatment module 40 in the needle 348 configuration may also be set up as corona discharge device in a manner similar to a traditional gap-discharge, corona discharge devices.
- the needle would gas treating module that utilize a glass dielectric on the high-voltage electrode and would be powered by low-frequency, high-voltage power.
- similar electrodes are used, however they are powered by low voltages, and do not require a dielectric like the high voltage electrodes.
- the device 410 includes a plunger 416 and a barrel 418 that define a chamber 414 for holding precursor material.
- the plunger 416 has a first end 420 and a second end 422.
- the barrel 418 has a first end 424 that is open for receiving the first end 420 of the plunger 416 such that the plunger 416 movably engages the barrel 418.
- the barrel 418 also includes a second end 426.
- the second end 426 of the barrel 418 may be configured with an outlet 446 that serves as the outlet 446 for the chamber 414.
- a needle 448 may include a first end 482 and a second end 484.
- the second end 484 of the needle 448 may be attached to the outlet 446 using a Luer or other mechanical connection or fitting.
- the material treatment module 40 is the needle 448.
- the needle 448 utilizes a flow-through electrochemical cell to create treated material in the form of a therapeutic agent.
- the electrochemical cell needle 448 includes an anode 470 and a cathode 472. Electric current is delivered to the anode 470 and cathode 472 by wires 476 attached to a power source 480.
- the chamber 414 is charged with precursor material or precursor or electrolyte 374.
- the needle 480 houses electrodes 470 and 472 that are used to produce a beneficial agent in situ, or in other words, within the body.
- additional electrolyte may or may not be supplied in chamber 414.
- the elctrodes 470 and 472 extend beyond the opening 486 to have greater access to body fluid for generating in situ treated material which can be a beneficial agent. It will be appreciated that the plunger 416/barrel 418 configuration is not necessary for this application because the treated material is generated beyond the end 486 of the needle 448.
- the syringe-type configuration may be desirable to provide additional saline solution or other liquid precursors by plunging of the plunger 416 into the barrel 418 for patients that are dehydrated or to areas of the body that don't have much material.
- the first end 482 of the needle may have a protective shield or shroud (not shown) that protects the electrodes 470 and 472 from being damaged upon insertion.
- a method of dispensing a material using a handheld dispensing apparatus is also disclosed.
- a dispensing apparatus or device 10, 310, 410, as discussed above may be used to dispense the material.
- the method includes collecting a precursor material in the chamber 14, 314, 414.
- the material treatment module 40, 340, 440 is activated.
- the precursor material collected in the chamber 14, 314, 414 is treated by the material treatment module to create a treated material.
- the needle 48, 348, 448 is positioned within a body.
- the treated material is then dispensed out of the device 10, 310, 410 or chamber into the body through the needle.
- the precursor material may include, without limitation, air, oxygen, water, nitrogen, carbon dioxide, chlorine, bromine, iodine, flourine and combinations thereof.
- It may also include a salt solution, either alone or in combination with the foregoing.
- the salt solution may include NaI, NaF, NaCl, NaBr, and the like. It will be appreciated by those of skill in the art that the term salt solution includes compounds formed when the hydrogen of an acid is replaced by a metal.
- Activating the material treatment module 40 includes engaging a switch to allow power from a power source to be delivered to the material treatment module.
- the method may also include deactivating the material treatment module, either manually or automatically.
- the method may also include detecting an amount of material treated by the material treatment module to determine when to shut off the module 40 or device 10. This may be accomplished by monitoring a display.
- dispensing the material may include moving the plunger relative to the barrel such that treated material is delivered through the needle into the body.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2007342491A AU2007342491B2 (en) | 2003-10-06 | 2007-12-19 | Apparatus and method for treating and dispensing a material into tissue |
EP07863148A EP2097125A4 (en) | 2006-12-26 | 2007-12-19 | Apparatus and method for treating and dispensing a material into tissue |
JP2009544036A JP2010514500A (en) | 2006-12-26 | 2007-12-19 | Apparatus and method for processing and dispensing material to biological tissue |
CA002674914A CA2674914A1 (en) | 2006-12-26 | 2007-12-19 | Apparatus and method for treating and dispensing a material into tissue |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/616,041 | 2006-12-26 | ||
US11/616,041 US8066659B2 (en) | 2004-06-15 | 2006-12-26 | Apparatus and method for treating and dispensing a material into tissue |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008085364A1 true WO2008085364A1 (en) | 2008-07-17 |
Family
ID=39615622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/025989 WO2008085364A1 (en) | 2003-10-06 | 2007-12-19 | Apparatus and method for treating and dispensing a material into tissue |
Country Status (6)
Country | Link |
---|---|
US (3) | US8066659B2 (en) |
EP (1) | EP2097125A4 (en) |
JP (1) | JP2010514500A (en) |
AU (1) | AU2007342491B2 (en) |
CA (1) | CA2674914A1 (en) |
WO (1) | WO2008085364A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010056676A2 (en) * | 2008-11-11 | 2010-05-20 | Ceramatec, Inc. | An apparatus and method to deliver a sterile, filled syringe to a user |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2314182T3 (en) | 2002-02-11 | 2009-03-16 | Antares Pharma, Inc. | INTRADERMIC INJECTOR. |
US7615030B2 (en) * | 2003-10-06 | 2009-11-10 | Active O, Llc | Apparatus and method for administering a therapeutic agent into tissue |
US8777889B2 (en) * | 2004-06-15 | 2014-07-15 | Ceramatec, Inc. | Apparatus and method for administering a therapeutic agent into tissue |
US8066659B2 (en) | 2004-06-15 | 2011-11-29 | Ceramatec, Inc. | Apparatus and method for treating and dispensing a material into tissue |
BRPI0614025A2 (en) | 2005-01-24 | 2012-12-25 | Antares Pharma Inc | jet injectors |
US8353906B2 (en) * | 2005-08-01 | 2013-01-15 | Ceramatec, Inc. | Electrochemical probe and method for in situ treatment of a tissue |
US9144648B2 (en) | 2006-05-03 | 2015-09-29 | Antares Pharma, Inc. | Injector with adjustable dosing |
WO2007131013A1 (en) | 2006-05-03 | 2007-11-15 | Antares Pharma, Inc. | Two-stage reconstituting injector |
US8057748B2 (en) * | 2007-10-24 | 2011-11-15 | Minimus Spine, Inc. | Syringe, system and method for delivering oxygen-ozone |
US8961471B2 (en) * | 2007-12-12 | 2015-02-24 | Minimus Spine, Inc. | Syringe device, system and method for delivering ozone gas |
EP2990067B1 (en) | 2008-03-10 | 2019-09-04 | Antares Pharma, Inc. | Injector safety device |
WO2009146432A1 (en) * | 2008-05-30 | 2009-12-03 | Colorado State University Research Foundation | Plasma-based chemical source device and method of use thereof |
EP3581224A1 (en) | 2008-08-05 | 2019-12-18 | Antares Pharma, Inc. | Multiple dosage injector |
US8579865B2 (en) | 2009-03-20 | 2013-11-12 | Antares Pharma, Inc. | Hazardous agent injection system |
US9220660B2 (en) | 2011-07-15 | 2015-12-29 | Antares Pharma, Inc. | Liquid-transfer adapter beveled spike |
US8496619B2 (en) | 2011-07-15 | 2013-07-30 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
FI2822618T3 (en) | 2012-03-06 | 2024-03-21 | Antares Pharma Inc | Prefilled syringe with breakaway force feature |
WO2013152323A1 (en) | 2012-04-06 | 2013-10-10 | Wotton Paul K | Needle assisted jet injection administration of testosterone compositions |
US9364611B2 (en) | 2012-05-07 | 2016-06-14 | Antares Pharma, Inc. | Needle assisted jet injection device having reduced trigger force |
WO2014124427A1 (en) | 2013-02-11 | 2014-08-14 | Travanty Michael | Needle assisted jet injection device having reduced trigger force |
US20140242551A1 (en) * | 2013-02-28 | 2014-08-28 | Richard D. Downs | Oral Care System and Method |
ES2742046T3 (en) | 2013-03-11 | 2020-02-12 | Antares Pharma Inc | Dose injector with pinion system |
WO2014165136A1 (en) | 2013-03-12 | 2014-10-09 | Antares Pharma, Inc. | Constant volume prefilled syringes and kits thereof |
MX2017008236A (en) * | 2014-12-23 | 2017-10-06 | Koninklijke Philips Nv | Method and system for oral ph change. |
CN105769303B (en) * | 2016-05-06 | 2019-04-30 | 广州医谷生物医疗科技有限公司 | A kind of visual Arterial puncture intubation device |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998010774A2 (en) * | 1996-09-12 | 1998-03-19 | Rid (Riskin Devices) Ltd. | Use of ozone for treating diseases of body cavity tissues, and apparatus therefore |
US6251090B1 (en) * | 1994-12-12 | 2001-06-26 | Robert Logan Avery | Intravitreal medicine delivery |
US20040245087A1 (en) * | 2001-09-10 | 2004-12-09 | Hag-Joo Lee | Water discharge in a dielectric barrier discharge system to generate an ozonated water |
US20040254525A1 (en) * | 2003-04-08 | 2004-12-16 | Uber Arthur E. | Fluid delivery systems, devices and methods for delivery of hazardous fluids |
US20050277912A1 (en) * | 2003-07-16 | 2005-12-15 | Sasha John | Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations |
US20060166088A1 (en) * | 2005-01-26 | 2006-07-27 | Hokanson Karl E | Electrode connector tabs |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB261970A (en) | 1926-03-17 | 1926-12-02 | Masahiko Okawa | A device for the hypodermic injection of ozone |
US2032723A (en) | 1934-05-05 | 1936-03-03 | Carl E Schweser | Serum injecting outfit |
US3682162A (en) * | 1968-12-13 | 1972-08-08 | Wellcome Found | Combined electrode and hypodermic syringe needle |
DE2543284A1 (en) | 1975-09-27 | 1977-03-31 | Walter Otto Fichtmueller | Oxygen-ozone mixture filling unit for injection syringes - has top and bottom syringe centring devices preventing leakage or breakage |
US4193397A (en) * | 1977-12-01 | 1980-03-18 | Metal Bellows Corporation | Infusion apparatus and method |
US4485815A (en) | 1982-08-30 | 1984-12-04 | Kurt Amplatz | Device and method for fluoroscope-monitored percutaneous puncture treatment |
DE3446272C1 (en) * | 1984-12-19 | 1986-02-13 | Anette Dr. Med. Dent. Weber | Procedure and toothbrush for removing germs in the oral cavity |
US4632980A (en) * | 1985-04-03 | 1986-12-30 | Immunologics | Ozone decontamination of blood and blood products |
US4644960A (en) | 1985-09-23 | 1987-02-24 | Arrow International, Inc. | Device for making electrical connection to an electrolyte, and system employing same |
US4938233A (en) | 1987-08-03 | 1990-07-03 | Techton, Inc. | Radiation shield |
ATE120375T1 (en) * | 1988-04-29 | 1995-04-15 | Medizone Int Inc | DEVICE FOR THE CONTROLLED GENERATION AND ADMINISTRATION OF OZONE. |
US5078714A (en) | 1990-03-02 | 1992-01-07 | Jefferson Katims | Method and apparatus for placement of a probe in the body and the medical procedure for guiding and locating a catheter or probe in the body |
US5536241A (en) | 1990-12-05 | 1996-07-16 | The General Hospital Corporation | Methods and devices for relaxing smooth muscle contractions |
US5106589A (en) * | 1990-12-11 | 1992-04-21 | Conrad Richard H | Method of controlling ozone generator |
US5163904A (en) * | 1991-11-12 | 1992-11-17 | Merit Medical Systems, Inc. | Syringe apparatus with attached pressure gauge |
US6204058B1 (en) * | 1992-02-07 | 2001-03-20 | Vasogen Ireland Limited | Treatment of autoimmune diseases |
US6915806B2 (en) | 1993-05-10 | 2005-07-12 | Arthrocare Corporation | Method for harvesting graft vessel |
US5578005A (en) | 1993-08-06 | 1996-11-26 | River Medical, Inc. | Apparatus and methods for multiple fluid infusion |
US6071280A (en) | 1993-11-08 | 2000-06-06 | Rita Medical Systems, Inc. | Multiple electrode ablation apparatus |
US5536267A (en) | 1993-11-08 | 1996-07-16 | Zomed International | Multiple electrode ablation apparatus |
US6641580B1 (en) | 1993-11-08 | 2003-11-04 | Rita Medical Systems, Inc. | Infusion array ablation apparatus |
US5439452A (en) * | 1994-01-31 | 1995-08-08 | Children's Medical Ventures, Inc. | Limit stop valve infusion device |
JPH08150213A (en) | 1994-11-30 | 1996-06-11 | Olympus Optical Co Ltd | Gene injector |
US5674195A (en) * | 1995-02-06 | 1997-10-07 | Truthan; Charles Edwin | Syringe apparatus and method of mixing liquid medicants within a syringe |
US5540898A (en) * | 1995-05-26 | 1996-07-30 | Vasogen Inc. | Ozone generator with in-line ozone sensor |
US20050004634A1 (en) | 1995-06-07 | 2005-01-06 | Arthrocare Corporation | Methods for electrosurgical treatment of spinal tissue |
JPH09108313A (en) * | 1995-10-24 | 1997-04-28 | Mitsubishi Electric Corp | Inhibition of microbial growth and device thereof |
US5868999A (en) * | 1996-03-19 | 1999-02-09 | Ozone Sterilization Products, Inc. | Ozone sterilizer and method for ozone sterilization |
US5797872A (en) * | 1996-04-26 | 1998-08-25 | Nippon Ozone Co., Ltd. | Method of treating domestic animals such as cows for mastitis and apparatus for injecting ozone into breasts |
US6726684B1 (en) | 1996-07-16 | 2004-04-27 | Arthrocare Corporation | Methods for electrosurgical spine surgery |
JP3298431B2 (en) * | 1996-10-21 | 2002-07-02 | 三菱電機株式会社 | Ozone / hydrogen peroxide generator |
ATE236646T1 (en) | 1996-12-03 | 2003-04-15 | Lisa Marlene Jeffreys Smith | COMPOUNDS CONTAINING REACTIVE OXYGEN COMPOUNDS FOR INDUCING CELL DIFFERENTIATION OF MALIGNANT CELLS SUCH AS LEUKEMIA |
US6110431A (en) * | 1997-05-05 | 2000-08-29 | Dunder; Ove Karl | Ozone dispensing system |
CA2206180A1 (en) * | 1997-05-27 | 1998-11-27 | Vasogen Inc. | Treatment of chronic post-traumatic pain syndromes |
US7614568B2 (en) * | 2000-08-24 | 2009-11-10 | Microlin, Llc | Device employing gas generating cell for facilitating controlled release of fluid into ambient environment |
US6134806A (en) * | 1997-07-14 | 2000-10-24 | Dhaemers; Gregory L. | Bag with air distributor and ozone generator |
AU8577098A (en) | 1997-07-22 | 1999-02-16 | Emed Corporation | Needle for iontophoretic delivery of agent |
US5971722A (en) * | 1997-09-05 | 1999-10-26 | Baxter International Inc | Electrochemical syringe pump having a sealed storage reservoir for a charge transfer medium |
US6136308A (en) * | 1997-09-12 | 2000-10-24 | Vasogen Ireland Limited | Treatment of stress and preconditioning against stress |
US20020037235A1 (en) * | 1997-10-23 | 2002-03-28 | Khatchatrian Robert G. | Ozone generator for treating clothing |
US20040071615A1 (en) * | 1997-10-23 | 2004-04-15 | Khatchatrian Robert G. | Ozone generator |
JPH11172482A (en) * | 1997-12-10 | 1999-06-29 | Shinko Plant Kensetsu Kk | Ozonized water producing device and production of ozonized water with the device |
JP3692237B2 (en) | 1998-04-03 | 2005-09-07 | 三菱重工業株式会社 | Ozone storage method and apparatus |
US6620379B1 (en) * | 1998-04-09 | 2003-09-16 | S.P.M. Recovery Ltd. | Apparatus and method of treatment of wounds, burns and immune system disorders |
US6073627A (en) * | 1998-07-30 | 2000-06-13 | Medizone International, Inc. | Apparatus for the application of ozone/oxygen for the treatment of external pathogenic conditions |
US6413228B1 (en) * | 1998-12-28 | 2002-07-02 | Pro Duct Health, Inc. | Devices, methods and systems for collecting material from a breast duct |
IL134009A (en) | 2000-01-12 | 2011-07-31 | Bo2 Technologies Ltd | Implantable device |
AU2002245243B2 (en) | 2001-01-11 | 2007-03-22 | Angiodynamics, Inc. | Bone-treatment instrument and method |
US7244354B2 (en) | 2001-01-12 | 2007-07-17 | Alab, Llc | Ozone irrigator |
US20020188323A1 (en) * | 2001-03-19 | 2002-12-12 | Remon Medical Technologies Ltd. | Methods, systems and devices for in vivo electrochemical production of therapeutic agents |
WO2002076533A1 (en) | 2001-03-27 | 2002-10-03 | Alessandro Giannessi | Magnetically operated, subcutaneously implantable drug infusion device |
US6875018B2 (en) * | 2001-03-28 | 2005-04-05 | Curozone Ireland Limited | Use of ozone for the treatment of root canals |
US6810288B2 (en) * | 2001-07-06 | 2004-10-26 | Ceramatec, Inc. | Device and method for wound healing and infection control |
GB0129590D0 (en) * | 2001-12-11 | 2002-01-30 | Cambridge Biopolymers Ltd | Oil Ozonolysis |
US6800064B2 (en) * | 2002-01-18 | 2004-10-05 | Che-Peng Liang | Disinfecting method for wound without using liquid disinfectant and the device thereof |
DE50203268D1 (en) * | 2002-03-15 | 2005-07-07 | Muehlbauer Ernst Gmbh & Co Kg | Multi-component mixing capsule, in particular for dental purposes |
US6912417B1 (en) * | 2002-04-05 | 2005-06-28 | Ichor Medical Systmes, Inc. | Method and apparatus for delivery of therapeutic agents |
ITMO20020321A1 (en) * | 2002-11-06 | 2004-05-07 | Sidam Di Azzolini Graziano E C S A S | GROUP FOR THE MIXING OF INSERIBLE FLUIDS ALONG LINES |
GB2402066B (en) | 2003-05-23 | 2006-06-07 | Bioquell Uk Ltd | Apparatus for disinfecting a surface |
US8066659B2 (en) | 2004-06-15 | 2011-11-29 | Ceramatec, Inc. | Apparatus and method for treating and dispensing a material into tissue |
US8777889B2 (en) | 2004-06-15 | 2014-07-15 | Ceramatec, Inc. | Apparatus and method for administering a therapeutic agent into tissue |
US7615030B2 (en) | 2003-10-06 | 2009-11-10 | Active O, Llc | Apparatus and method for administering a therapeutic agent into tissue |
JP2005307232A (en) | 2004-04-19 | 2005-11-04 | Mitsubishi Electric Corp | Water electrolyzer and driving method therefor |
US20060251551A1 (en) * | 2005-05-09 | 2006-11-09 | Brian Johnson | Apparatus and method for ozone gas distribution |
US8353906B2 (en) * | 2005-08-01 | 2013-01-15 | Ceramatec, Inc. | Electrochemical probe and method for in situ treatment of a tissue |
-
2006
- 2006-12-26 US US11/616,041 patent/US8066659B2/en active Active
-
2007
- 2007-12-19 CA CA002674914A patent/CA2674914A1/en not_active Abandoned
- 2007-12-19 EP EP07863148A patent/EP2097125A4/en not_active Withdrawn
- 2007-12-19 JP JP2009544036A patent/JP2010514500A/en active Pending
- 2007-12-19 WO PCT/US2007/025989 patent/WO2008085364A1/en active Application Filing
- 2007-12-19 AU AU2007342491A patent/AU2007342491B2/en not_active Ceased
-
2011
- 2011-07-22 US US13/188,999 patent/US20120022437A1/en not_active Abandoned
- 2011-07-22 US US13/189,290 patent/US8591472B2/en not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6251090B1 (en) * | 1994-12-12 | 2001-06-26 | Robert Logan Avery | Intravitreal medicine delivery |
WO1998010774A2 (en) * | 1996-09-12 | 1998-03-19 | Rid (Riskin Devices) Ltd. | Use of ozone for treating diseases of body cavity tissues, and apparatus therefore |
US20040245087A1 (en) * | 2001-09-10 | 2004-12-09 | Hag-Joo Lee | Water discharge in a dielectric barrier discharge system to generate an ozonated water |
US20040254525A1 (en) * | 2003-04-08 | 2004-12-16 | Uber Arthur E. | Fluid delivery systems, devices and methods for delivery of hazardous fluids |
US20050277912A1 (en) * | 2003-07-16 | 2005-12-15 | Sasha John | Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations |
US20060166088A1 (en) * | 2005-01-26 | 2006-07-27 | Hokanson Karl E | Electrode connector tabs |
Non-Patent Citations (1)
Title |
---|
See also references of EP2097125A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010056676A2 (en) * | 2008-11-11 | 2010-05-20 | Ceramatec, Inc. | An apparatus and method to deliver a sterile, filled syringe to a user |
WO2010056676A3 (en) * | 2008-11-11 | 2010-08-19 | Ceramatec, Inc. | An apparatus and method to deliver a sterile, filled syringe to a user |
Also Published As
Publication number | Publication date |
---|---|
US20120022438A1 (en) | 2012-01-26 |
JP2010514500A (en) | 2010-05-06 |
US8591472B2 (en) | 2013-11-26 |
US20120022437A1 (en) | 2012-01-26 |
EP2097125A1 (en) | 2009-09-09 |
US8066659B2 (en) | 2011-11-29 |
CA2674914A1 (en) | 2008-07-17 |
AU2007342491A1 (en) | 2008-07-17 |
US20070154363A1 (en) | 2007-07-05 |
AU2007342491B2 (en) | 2013-08-29 |
EP2097125A4 (en) | 2012-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8591472B2 (en) | Apparatus for administering a therapeutic agent into tissue using a needle as the material treatment module | |
EP2265327B1 (en) | Electrochemical probe for in situ treatment of a tissue | |
US8986520B2 (en) | Apparatus administering a therapeutic agent into tissue | |
EP1670526B1 (en) | Apparatus and method for administering a therapeutic agent | |
AU2008317346B2 (en) | Syringe, system and method for delivering oxygen-ozone | |
EP1946788B1 (en) | Syringe for administering a therapeutic agent into tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07863148 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2674914 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007342491 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2009544036 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007342491 Country of ref document: AU Date of ref document: 20071219 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007863148 Country of ref document: EP |